Avoiding permanent atrial fibrillation: treatment approaches to prevent disease progression

• Published in: Vascular health and risk management Vol. 10; no. default; pp. 1 - 12
• Main Authors: Shukla, Ashish, Curtis, Anne B
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2014; Taylor & Francis Ltd; Dove Press; Dove Medical Press
• Subjects: Age; Anti-Arrhythmia Agents - adverse effects; Anti-Arrhythmia Agents - therapeutic use; Atrial fibrillation; Atrial Fibrillation - complications; Atrial Fibrillation - diagnosis; Atrial Fibrillation - mortality; Atrial Fibrillation - physiopathology; Atrial Fibrillation - therapy; Cardiac arrhythmia; Cardiovascular disease; Care and treatment; Catheter Ablation - adverse effects; Catheter Ablation - mortality; Catheters; Development and progression; Diabetes; Disease prevention; Disease Progression; Drug therapy; Epidemiology; Growth factors; Heart; Heart Failure - etiology; Heart Failure - mortality; Heart Failure - prevention & control; Heart Rate - drug effects; Humans; Hypertension; Incidence; Inflammation; Morbidity; Mortality; Patients; permanent; Prevalence; prevention; Preventive Health Services; progression; Review; Risk Factors; Sleep apnea; Stroke - etiology; Stroke - mortality; Stroke - prevention & control; Treatment Outcome; progression; atrial fibrillation; permanent; prevention
• ISSN: 1178-2048; 1176-6344; 1178-2048
• DOI: 10.2147/VHRM.S49334

Atrial fibrillation (AF) is the most common sustained arrhythmia and a major global public health problem due to its associated morbidity, including stroke and heart failure, diminished quality of life, and increased mortality. AF often presents initially in a paroxysmal form and may progress to a more sustained form over time. Evidence from randomized controlled trials suggests that there may be no mortality benefit to using a rhythm control approach in comparison with rate control of AF. Nevertheless, sustained forms of AF may be associated with increased symptoms and cardiovascular morbidity, and consequently they remain an additional target for therapy. The present review evaluates the clinical correlates of arrhythmia progression and risk stratification techniques available to assess probability of AF progression. Further, currently available management options for arrhythmia control in AF are evaluated and their therapeutic effect and efficacy on disease progression are explored.